Ozuriftamab (BA302) is a human immunoglobulin IgG1 kappa monoclonal antibody specifically designed to target the receptor tyrosine kinase-like orphan receptor 2 (ROR2), and this antibody serves as the foundational targeting moiety for the synthesis of antibody-drug conjugates (ADCs), such as Ozuriftamab vedotin.